inhalation solution clinical trials

A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis

This study is testing a new inhaled medicine (CSL787) for adults aged 18-85 with a lung condition called non-cystic fibrosis bronchiectasis. Researchers want to see if the medicine can reduce flare-ups, improve breathing, and if it's safe to use compared to a dummy treatment.